A dose-ranging study of ticagrelor in children aged 3-17 years with sickle cell disease: A 2-part phase 2 study.

Am J Hematol · 2018 · PMC6282821 · PMID 30187935

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

8 In addition, the reduction in VOC rate did not reach statistical significance in the DOVE trial. 8 A potential limitation of the DOVE trial was that the observed level of platelet inhibition (P2Y 12 reaction units [PRU]) was only ~20% from baseline. 9 Thus, it is of interest to assess the potential clinical consequences of a higher level of platelet inhibition in patients with SCD.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.